On May 6, 2020, BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the closing of the Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) acquisition through an all-stock transaction. The merger agreement was first announced on January 16, 2020. The new subsidiary based in Cambridge, Massachusetts, will operate under the name of BioNTech US Inc. and serve as BioNTech’s U.S. headquarters. As of May 7, 2020, Neon’s common stock will no longer be available for trading.
Duff & Phelps served as an independent financial advisor to the board of directors of Neon Therapeutics, Inc. and provided a fairness opinion in connection with the transaction.
About Neon Therapeutics, Inc.
Neon Therapeutics, Inc. is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Goodwin Procter LLP served as a legal advisor to Neon Therapeutics, Inc.
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. Covington & Burling LLP served as a legal advisor to BioNTech.
Fairness and Solvency Opinions
Independent opinions for boards of directors and special committees.
Transaction Advisory Services
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Comprehensive support throughout mergers and acquisitions and other corporate transactions.
Healthcare expertise for middle-market M&A transactions.
Strategic Value Advisory
Assistance evaluating strategic alternatives and identifying growth strategies.
has completed a debt for equity exchange as part of a restructuring transaction
has completed a recapitalization and financial restructuring transaction
has been acquired by
a portfolio company of
has signed a binding offer to acquire five data centers from
Macy’s, Inc. (NYSE:M), has completed a refinancing transaction, raising approximately $4.5 billion of new financing, including an asset-based credit line and the issuance of senior secured notes
has sold its passive infrastructure to
Duff & Phelps Partners with NYU Stern School of Business
Bob Bartell Shares His Views on Restructuring an ESOP Company
Jacco Brouwer Discusses COVID-19 Impact on European Mid-Market Debt
Bob Bartell Shares His Views on Publicly Traded Business Development Companies